Globo H IHC Assay

DEVICE2 trials

Sponsors

OBI Pharma, Inc

Conditions

Locally Advanced Solid TumorsMetastatic Solid TumorsTriple Negative Breast Cancer

Phase 1

This Study is to Evaluate Safe and Effective Treatment Dose of OBI-888 in Patients With Locally Advanced or Metastatic Solid Tumors.

TerminatedNCT03573544

OBI Pharma, IncLocally Advanced Solid Tumors, Metastatic Solid Tumors

Start: 2018-05-07End: 2022-04-07Updated: 2024-02-22

Phase 3

Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC

Active, not recruitingNCT03562637

OBI Pharma, IncTriple Negative Breast Cancer

Start: 2018-12-05End: 2027-12-30Updated: 2025-05-09

Related Papers

A phase 3 trial of adagloxad simolenin/OBI-821 in patients with high-risk early-stage triple-negative breast cancer.

Journal of Clinical Oncology2026-05-27

Exploring New Frontiers: Alternative Breast Cancer Treatments Through Glycocalyx Research.

2025-05-221 citations

A phase 3, randomized, open-label study of the anti-Globo H vaccine adagloxad simolenin/obi-821 in the adjuvant treatment of high-risk, early-stage, Globo H-positive triple-negative breast cancer.

Journal of Clinical Oncology2022-06-018 citations

Abstract 2946: The prevalence of Globo H in different tumor types: Breast, pancreatic, lung, gastric, colorectal, liver, and esophageal cancers

Cancer Research2020-08-152 citations

Abstract 544: Anti-tumor efficacy and potential mechanism of action of a novel therapeutic humanized anti-Globo H antibody, OBI-888

Cancer Research2019-07-013 citations

Abstract 544: Anti-tumor efficacy and potential mechanism of action of a novel therapeutic humanized anti-Globo H antibody, OBI-888

Clinical Research (Excluding Clinical Trials)2019-07-013 citations